Login to Your Account



Medivir, Tibotec Expand HCV Work in Potential $430M Deal

By Jennifer Boggs


Tuesday, May 20, 2008
Their first collaborative effort in the hepatitis C virus space has spawned a promising Phase IIa-stage protease inhibitor, so Medivir AB and Tibotec BVBA are joining forces again in a potential €277 million (US$430 million) HCV deal aimed at developing polymerase inhibitors targeting NS5B. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription